Actualización en esclerosis múltiple: manifestaciones clínicas, formas evolutivas y estudios paraclínicos

  1. Alberte Woodward, M. 1
  2. Naveiro Soneira, J. 1
  3. Prieto González, J.M.Ó. 1
  1. 1 Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2023

Issue Title: Enfermedades del sistema nervioso (IX): Enfermedades desmielinizantes

Series: 13

Issue: 78

Pages: 4621-4627

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Multiple sclerosis is the classic autoimmune disease of the central nervous system. Besides geographical, genetic and environmental-related propensity, it has recently been confirmed that the most important risk factor for the development of the disease is infection by the Epstein-Barr virus. The classic diagnostic criteria of at least two episodes of neurological dysfunction disseminated in time and affecting different anatomical locations have been updated in recent decades, considering paraclinical techniques that allow early diagnosis and initiation of treatment, which results in a better prognosis of the illness. Current understanding is that the clinical forms of multiple sclerosis are part of a continuous spectrum in which relapses of the disease and progression of disability coexist to different degrees.

Bibliographic References

  • Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
  • Kantarci OH. Phases and phenotypes of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):636-54.
  • Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34(4):919-39.
  • Prieto González JM, Muñoz García D. Manifestaciones clínicas. En: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p. 11-6.
  • Nourbakhsh B, Mowry EM. Multiple sclerosis risk factors and pathogenesis. Continuum (Minneap Minn). 2019;25(3):596-610.
  • Ontaneda D. Progressive multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):736-52.
  • Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.Science.2022;375(6578):296-301.
  • Solomon AJ. Diagnosis, differential diagnosis, and misdiagnosis of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):611-35.
  • Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.
  • Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86.
  • Auger C, Rovira À. Nuevos conceptos sobre el papel de la resonancia magnética en el diagnóstico y seguimiento de la esclerosis múltiple. Radiología. 2020;62(5):349-59.
  • Rovira Cañellas À, Tintoré Subirana M. Resonancia magnética en la esclerosis múltiple. En: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p. 37-55.
  • Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurologica Scandinavica. 2010;122(1):1-8.
  • Oreja Guevara C, Izquierdo G. Estudio del líquido cefalorraquídeo en la esclerosis múltiple. Generalidades. En: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p. 31-4.
  • Villar Guimerans LM, Álvarez Cermeño JC. Estudio del líquido cefalorraquídeo en la esclerosis múltiple. Bandas oligoclonales. En: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p.35-6.
  • Villar LM, Masjuan J, Sádaba MC, González Porqué P, Plaza J, Bootello A. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol. 2005;62(4):574-7.
  • Skeen MB, Pani L. Biomarkers and surrogate end points in multiple sclerosis trials: Regulatory issues. J Clin Neurophysiol. 2021;38(3):181-5.
Data source: Dialnet